Compare · AGMB vs ARGX
AGMB vs ARGX
Side-by-side comparison of AgomAb Therapeutics NV (AGMB) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGMB and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.42B, about 89.9x AGMB ($538.5M).
- Over the past year, AGMB is down 27.0% and ARGX is up 25.7% - ARGX leads by 52.7 points.
- AGMB has been more active in the news (4 items in the past 4 weeks vs 2 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 3 for AGMB).
- Company
- AgomAb Therapeutics NV
- argenx SE
- Price
- $11.11+5.81%
- $780.08-1.00%
- Market cap
- $538.5M
- $48.42B
- 1M return
- -12.79%
- +11.90%
- 1Y return
- -26.96%
- +25.72%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2017
- News (4w)
- 4
- 2
- Recent ratings
- 3
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest AGMB
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
- SEC Form 20-F filed by AgomAb Therapeutics NV
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
- Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
- SEC Form 3 filed by new insider Bond Colin Michael
- SEC Form 3 filed by new insider Van Der Horst Paul Henryk
- SEC Form 3 filed by new insider Knotnerus Tim Jasper
- SEC Form 3 filed by new insider Borderias Andrea Saez
- SEC Form 3 filed by new insider Verduyn-Van Weegen Felice Isabel
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
- SEC Form 6-K filed by argenx SE